Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03415815
Other study ID # HenanEC
Secondary ID
Status Recruiting
Phase N/A
First received January 11, 2018
Last updated January 23, 2018
Start date December 12, 2017
Est. completion date April 30, 2018

Study information

Verified date January 2018
Source Henan Cancer Hospital
Contact Haiying Yang
Phone 0086-10-62680809
Email celineyang@linkdoc.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The real-world observational study was designed to explore lymph metastases and prognoses of the Chinese patients with thoracic T1-T3 esophageal cancer


Description:

This trial is a real-world non-interventional observational study. The Chinese patients with thoracic T1-T3 esophageal cancer enrolled from Jan.1999 to Jun.2017 were included and the study data on pathologically diagnosed patient demographic/tumor biological characteristics were collected to evaluate the relevance of lymph metastases and prognoses of the subjects.


Recruitment information / eligibility

Status Recruiting
Enrollment 3673
Est. completion date April 30, 2018
Est. primary completion date April 30, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients >= 18 years old;

- Patients who received radical resection of esophageal cancer;

- Pathologically diagnosed patients with thoracic T1-T3 esophageal cancer after surgeries;

Exclusion Criteria:

- Patients who received upper gastrointestinal surgeries;

- Patients with second primary tumors;

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Surgeries
Radical resection of esophageal cancer

Locations

Country Name City State
China China PLA General Hospital Beijing Beijing
China China-Japan Friendship Hospital Beijing Beijing
China Huaxi Hospital Affiliated to Sichuan University Chendu Sichuan
China First Hospital Affiliated to Zhejiang University Hangzhou Zhejiang
China Jiangsu cancer hospital Nanjing Jiangsu
China Shanghai Chest Hospital Shanghai Shanghai
China Tianjin Chest Hospital Tianjin Tianjin
China Tongji Hospital Affiliated to Huazhong Technology Hospital Wuhan Hubei
China Xi'an Tangdu Hospital Xi'an Shaanxi
China Henan cancer hospital Zhengzhou Henan

Sponsors (2)

Lead Sponsor Collaborator
Henan Cancer Hospital LinkDoc Technology (Beijing) Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Effects of lymph metastases on overall survival Effects on lymph metastases on overall survival in the patients with thoracic esophageal cancer 1999 - 2017
Other Effects of the numbers of lymph nodes on overall survival Effects of the numbers of lymph nodes on overall survival in the patients with thoracic esophageal cancer who received lymphadenectomy 1999 - 2017
Other Effects of surgeries on the percentages of the patients with esophageal cancer who received lymphadenectomy Effects of surgeries on the percentages of the thoracic T1-T3 patients with esophageal cancer who received lymphadenectomy 1999 - 2017
Other Effects of surgeries on the extents of the patients with esophageal cancer who received surgeries Effects of surgeries on the extents of the thoracic T1-T3 patients with esophageal cancer who received surgeries 1999 - 2017
Primary Numbers of lymph nodes and percentages of patients with surgeries Numbers of lymph nodes and percentages of patients with surgeries in the patients with thoracic T1-T3 esophageal cancer 1999 - 2017
Secondary Impact factors of lymph metastases Impact factors of lymph metastases 1999 - 2017
See also
  Status Clinical Trial Phase
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
Not yet recruiting NCT05542680 - Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer N/A
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT00003864 - Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus Phase 2
Recruiting NCT05491616 - Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Completed NCT00400114 - Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT04615806 - The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy N/A
Active, not recruiting NCT04566367 - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer N/A
Active, not recruiting NCT03962179 - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent) N/A
Terminated NCT01446874 - Prevention of Post-operative Pneumonia (POPP) Phase 2/Phase 3
Completed NCT03468634 - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy N/A
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT02544737 - Apatinib for Metastatic Esophageal Cancer. Phase 2